खोज परिणाम - Tadeusz Robak

परिणाम को परिष्कृत करें
  1. 1
    Second Malignancies and Richter's Syndrome in Patients with Chronic Lymphocytic Leukemia

    Second Malignancies and Richter's Syndrome in Patients with Chronic Lymphocytic Leukemia द्वारा Tadeusz Robak

    प्रकाशित 2004
    पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें
    Revisão
    सूची में सहेजें
    में बचाया:
  2. 2
    Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of a prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (PALG CLL2)

    Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of a prospectiv... द्वारा Tadeusz Robak

    प्रकाशित 2006
    पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें
    Artigo
    सूची में सहेजें
    में बचाया:
  3. 3
    Pharmacogenomics of<i>MDR1</i>/<i>ABCB1</i>Gene: the Influence on Risk and Clinical Outcome of Haematological Malignancies

    Pharmacogenomics of<i>MDR1</i>/<i>ABCB1</i>Gene: the Influence on Risk and Clinical Outcome of Haematological Malignancies द्वारा Krzysztof Jamroziak, Tadeusz Robak

    प्रकाशित 2004
    पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें
    Revisão
    सूची में सहेजें
    में बचाया:
  4. 4
    Safety and Tolerability of Antibody-Drug Conjugates in Cancer

    Safety and Tolerability of Antibody-Drug Conjugates in Cancer द्वारा Anna Wolska, Tadeusz Robak

    प्रकाशित 2019
    पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें
    Revisão
    सूची में सहेजें
    में बचाया:
  5. 5
    Bortezomib for the Treatment of Hematologic Malignancies: 15 Years Later

    Bortezomib for the Treatment of Hematologic Malignancies: 15 Years Later द्वारा Paweł Robak, Tadeusz Robak

    प्रकाशित 2019
    पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें
    Revisão
    सूची में सहेजें
    में बचाया:
  6. 6
    Bruton’s Kinase Inhibitors for the Treatment of Immunological Diseases: Current Status and Perspectives

    Bruton’s Kinase Inhibitors for the Treatment of Immunological Diseases: Current Status and Perspectives द्वारा Ewa Robak, Tadeusz Robak

    प्रकाशित 2022
    पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें
    Revisão
    सूची में सहेजें
    में बचाया:
  7. 7
    The Role of Bruton’s Kinase Inhibitors in Chronic Lymphocytic Leukemia: Current Status and Future Directions

    The Role of Bruton’s Kinase Inhibitors in Chronic Lymphocytic Leukemia: Current Status and Future Directions द्वारा Tadeusz Robak, Magdalena Witkowska, Piotr Smolewski

    प्रकाशित 2022
    पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें
    Revisão
    सूची में सहेजें
    में बचाया:
  8. 8
    PI3K Inhibitors for the Treatment of Chronic Lymphocytic Leukemia: Current Status and Future Perspectives

    PI3K Inhibitors for the Treatment of Chronic Lymphocytic Leukemia: Current Status and Future Perspectives द्वारा Iwona Hus, Bartosz Puła, Tadeusz Robak

    प्रकाशित 2022
    पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें
    Revisão
    सूची में सहेजें
    में बचाया:
  9. 9
    Treatment of Double-Refractory Chronic Lymphocytic Leukemia—An Unmet Clinical Need

    Treatment of Double-Refractory Chronic Lymphocytic Leukemia—An Unmet Clinical Need द्वारा Przemysław Zygmunciak, Tadeusz Robak, Bartosz Puła

    प्रकाशित 2024
    पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें
    Artigo
    सूची में सहेजें
    में बचाया:
  10. 10
    Toll-like receptors and their role in carcinogenesis and anti-tumor treatment

    Toll-like receptors and their role in carcinogenesis and anti-tumor treatment द्वारा Anna Wolska, Ewa Lech‐Marańda, Tadeusz Robak

    प्रकाशित 2008
    पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें
    Revisão
    सूची में सहेजें
    में बचाया:
  11. 11
    Serum levels of interleukin‐6 type cytokines and soluble interleukin‐6 receptor in patients with rheumatoid arthritis

    Serum levels of interleukin‐6 type cytokines and soluble interleukin‐6 receptor in patients with rheumatoid arthritis द्वारा Tadeusz Robak, A Gladalska, H Stępień, Ewa Robak

    प्रकाशित 1998
    पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें
    Artigo
    सूची में सहेजें
    में बचाया:
  12. 12
    Extramedullary and extranodal manifestations in chronic lymphocytic leukemia – an update

    Extramedullary and extranodal manifestations in chronic lymphocytic leukemia – an update द्वारा Tadeusz Robak, Anna Puła, Marcin Braun, Ewa Robak

    प्रकाशित 2024
    पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें
    Revisão
    सूची में सहेजें
    में बचाया:
  13. 13
    Current Status of Older and New Purine Nucleoside Analogues in the Treatment of Lymphoproliferative Diseases

    Current Status of Older and New Purine Nucleoside Analogues in the Treatment of Lymphoproliferative Diseases द्वारा Tadeusz Robak, Anna Korycka, Ewa Lech‐Marańda, Paweł Robak

    प्रकाशित 2009
    पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें
    Revisão
    सूची में सहेजें
    में बचाया:
  14. 14
    Chronic lymphocytic leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Chronic lymphocytic leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up द्वारा Barbara Eichhorst, Martin Dreyling, Tadeusz Robak, Emili Montserrat, Michael Hallek

    प्रकाशित 2011
    पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें
    Artigo
    सूची में सहेजें
    में बचाया:
  15. 15
    Hairy cell leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Hairy cell leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up द्वारा Tadeusz Robak, Estella Matutes, Daniel Catovsky, Pier Luigi Zinzani, Christian Buske

    प्रकाशित 2015
    पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें
    Artigo
    सूची में सहेजें
    में बचाया:
  16. 16
    Expression of Toll-Like Receptors 3, 7, and 9 in Peripheral Blood Mononuclear Cells from Patients with Systemic Lupus Erythematosus

    Expression of Toll-Like Receptors 3, 7, and 9 in Peripheral Blood Mononuclear Cells from Patients with Systemic Lupus Erythematosus द्वारा Agnieszka Klonowska-Szymczyk, Anna Wolska, Tadeusz Robak, Barbara Cebula‐Obrzut, Piotr Smolewski, Ewa Robak

    प्रकाशित 2014
    पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें
    Artigo
    सूची में सहेजें
    में बचाया:
  17. 17
    Alemtuzumab Compared With Chlorambucil As First-Line Therapy for Chronic Lymphocytic Leukemia

    Alemtuzumab Compared With Chlorambucil As First-Line Therapy for Chronic Lymphocytic Leukemia द्वारा Peter Hillmen, Aleksander B. Skotnicki, Tadeusz Robak, Branimir Jakšić, Anna Dmoszyńska, Jingyang Wu, Cynthia A. Sirard, Jiřı́ Mayer

    प्रकाशित 2007
    पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें
    Artigo
    सूची में सहेजें
    में बचाया:
  18. 18
    Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy

    Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide th... द्वारा Pieter Sonneveld, Roman Hájek, Arnon Nagler, Andrew Spencer, Joan Bladé, Tadeusz Robak, Sen Hong Zhuang, Jean‐Luc Harousseau, Robert Z. Orlowski

    प्रकाशित 2008
    पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें
    Artigo
    सूची में सहेजें
    में बचाया:
  19. 19
    High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: integrating molecular and cellular therapies

    High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: integrating molecular and cellular therapies द्वारा Peter Dreger, Paolo Ghia, Johannes Schetelig, Michel van Gelder, Eva Kimby, Mauricette Michallet, Carol Moreno, Tadeusz Robak, Stephan Stilgenbauer, Emili Montserrat

    प्रकाशित 2018
    पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें
    Revisão
    सूची में सहेजें
    में बचाया:
  20. 20
    Acalabrutinib plus venetoclax and rituximab in treatment-naive mantle cell lymphoma: 2-year safety and efficacy analysis

    Acalabrutinib plus venetoclax and rituximab in treatment-naive mantle cell lymphoma: 2-year safety and efficacy analysis द्वारा Michael Wang, Tadeusz Robak, Kami J. Maddocks, Tycel Phillips, Stephen D. Smith, David Gallinson, Roser Calvo, Chuan‐Chuan Wun, Veerendra Munugalavadla, Wojciech Jurczak

    प्रकाशित 2024
    पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें
    Artigo
    सूची में सहेजें
    में बचाया:

खोज साधन: